LPCN Company Profile and Key Details
Lipocine Inc.
LPCN Stock Price Chart
Stock Price Today
Lipocine Inc. (LPCN) stock surged +5.26%, trading at $4.60 on NASDAQ, up from the previous close of $4.37. The stock opened at $4.38, fluctuating between $4.32 and $4.73 in the recent session.
Stock Snapshot
Stock Price History Chart
Contact Details
About Company
Lipocine Inc., a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of neuroendocrine and metabolic disorders. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Its lead product candidate is TLANDO, an oral testosterone replacement therapy. The company's pipeline candidates also include LPCN 1144, an oral prodrug of bioidentical testosterone that has completed Phase II clinical trial for the treatment of non-cirrhotic non-alcoholic steatohepatitis; LPCN 1111, an oral prodrug of testosterone tridecanoate for once daily dosing, which has completed Phase II clinical trial in hypogonadal men; LPCN 1148, a novel prodrug of testosterone and testosterone laurate for the management of decompensated cirrhosis; LPCN 1154, an investigational new drug application to conduct a Phase 2 study in Postpartum depression; LPCN 2101 for women with epilepsy, which has completed pre-clinical study; and LPCN 1107, an oral hydroxyprogesterone caproate product that has completed dose finding Phase II clinical trial for the prevention of recurrent preterm birth. The company is headquartered in Salt Lake City, Utah.
Company Information
| Employees | 17 |
| Beta | 1.19 |
| Sales or Revenue | $109.99K |
| 5Y Sales Change% | -2.576% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |
Frequently Asked Questions
Lipocine Inc. (NASDAQ: LPCN) stock price is $4.60 in the last trading session. During the trading session, LPCN stock reached the peak price of $4.73 while $4.32 was the lowest point it dropped to. The percentage change in LPCN stock occurred in the recent session was 5.26% while the dollar amount for the price change in LPCN stock was $0.23.
The NASDAQ listed LPCN is part of Biotechnology industry that operates in the broader Healthcare sector. Lipocine Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Dr. Nachiappan Chidambaram Ph.D.
Senior Vice President of R&D
Ms. Krista Fogarty
Principal Accounting Officer & Corporation Controller
Mr. Logan Morse
Vice President of Sales, Marketing & Operations
Dr. Anthony DelConte M.D., M. D.
Chief Medical Director
Mr. Nachiappan Chidambaram Ph.D.
Vice President of Product Devel.
Dr. Mahesh V. Patel Ph.D.
Co-Founder, Interim Principal Financial Officer, Director, Pres & Chief Executive Officer
Dr. George G. Nomikos M.D., Ph.D.
Senior Vice President of Medical & Clinical Sciences and Head of Muscle Therapeutic Area
LPCN's closing price is 43.75% higher than its 52-week low of $3.20 where as its distance from 52-week high of $11.79 is -60.98%.
Number of LPCN employees currently stands at 17.
Official Website of LPCN is: https://www.lipocine.com
LPCN could be contacted at phone 801 994 7383 and can also be accessed through its website. LPCN operates from 675 Arapeen Drive, Salt Lake City, UT 84108, United States.
LPCN stock volume for the day was 19.46K shares. The average number of LPCN shares traded daily for last 3 months was 30.26K.
The market value of LPCN currently stands at $24.60M with its latest stock price at $4.60 and 5.35M of its shares outstanding.
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com